SBRT and Anlotinib Hydrochloride combined with Toripalimab for the first-line treatment of patients with locally advanced or metastatic hepatic carcinoma: a prospective, single arm, single center, exploratory clinical study
Latest Information Update: 04 Aug 2020
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Aug 2020 New trial record